Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
NCT05672927
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Immunization
- HPV Infection
- Human Papillomavirus
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 27 to 45 years
- Sex
- Female
- Healthy volunteers
- Accepted
- Sponsor
- The University of Texas Medical Branch, Galveston
- Last updated on ClinicalTrials.gov
- September 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 1
- University of Texas Medical Branch · Galveston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.